Westfield Capital Management Co. LP Has $69.36 Million Stake in Icon Plc $ICLR

Westfield Capital Management Co. LP lifted its position in shares of Icon Plc (NASDAQ:ICLR) by 14.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 396,354 shares of the medical research company’s stock after buying an additional 50,526 shares during the quarter. Westfield Capital Management Co. LP owned about 0.49% of Icon worth $69,362,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. boosted its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares during the last quarter. Spire Wealth Management raised its position in shares of Icon by 10.1% in the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock worth $119,000 after acquiring an additional 62 shares in the last quarter. Private Trust Co. NA lifted its stake in shares of Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares during the period. Sierra Legacy Group boosted its position in shares of Icon by 2.5% during the 3rd quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock valued at $794,000 after purchasing an additional 110 shares in the last quarter. Finally, SkyView Investment Advisors LLC boosted its position in shares of Icon by 1.8% during the 2nd quarter. SkyView Investment Advisors LLC now owns 6,321 shares of the medical research company’s stock valued at $914,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ICLR. BMO Capital Markets reiterated a “market perform” rating and issued a $100.00 target price on shares of Icon in a report on Thursday, February 12th. Truist Financial reaffirmed a “hold” rating and set a $222.00 price objective (down from $231.00) on shares of Icon in a research report on Thursday, January 8th. Barclays boosted their target price on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Finally, Jefferies Financial Group set a $135.00 price target on shares of Icon and gave the stock a “buy” rating in a report on Monday. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Icon presently has a consensus rating of “Hold” and an average price target of $157.47.

Icon Price Performance

ICLR stock opened at $101.00 on Thursday. The company has a market capitalization of $8.16 billion, a P/E ratio of 13.67, a price-to-earnings-growth ratio of 2.60 and a beta of 1.27. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a 52-week low of $66.57 and a 52-week high of $211.00. The business has a 50-day simple moving average of $162.21 and a two-hundred day simple moving average of $171.14.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.